Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 9, December, p. 1359–1366

doi: 10.17219/acem/65441

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

An inverse relationship between plasma glutathione concentration and fasting glycemia in patients with coronary artery disease and concomitant type 2 diabetes: A pilot study

Kamil Karolczak1,A,B,C,D,E,F, Paweł Kubalczyk2,B,E,F, Rafał Głowacki2,B,E,F, Robert Pietruszyński3,B,E,F, Cezary Watała1,B,C,D,E,F

1 Department of Hemostatic Disorders, Medical University of Lodz, Poland

2 Department of Environmental Chemistry, Faculty of Chemistry, University of Lodz, Poland

3 Department of Radiological and Nuclear Diagnostics and Therapy, Central Veterans’ Hospital, Łódź, Poland

Abstract

Background. There have been occasional reports indicating that plasma concentrations of reduced glutathione (GSH) may be associated in some way with blood glucose. This relationship, however, has not hitherto been explored in the blood plasma of patients with coronary artery disease (CAD).
Objectives. The aim of this study was to evaluate potential associations of fasting glycemia and peripheral blood plasma GSH concentrations in CAD-free and CAD-affected subjects.
Material and Methods. In blood samples obtained from patients with CAD, defined by coronary angiography and/or echocardiography, and from an age-matched control group of patients with a confirmation of no coronary artery occlusion and with no history of cardiovascular events, plasma concentrations of glucose and reduced glutathione were analyzed by routine laboratory diagnostic methods and high performance liquid chromatography (HPLC), respectively.
Results. The results showed that in the CAD patients, but not in the non-CAD controls, fasting glycemia is negatively associated with plasma levels of GSH (r = -0.328; p = 0.011). Moreover, in the CAD-affected subjects (but not in the controls) the presence of type 2 diabetes mellitus significantly discriminated plasma levels of GSH (rP = -0.125; p = 0.350, between GSH and glucose adjusted for the occurrence of diabetes).
Conclusion. The study suggests that GSH may be an important factor contributing to glucose metabolism in CAD patients. Hence, it may be considered a significant therapeutic target in strategies aimed at improving glycemic control in CAD-affected subjects.

Key words

atherosclerosis, glucose, glutathione, cardiovascular risk factors, diabetes mellitus

References (25)

  1. Quadros AS, Sarmento-Leite R, Bertoluci M, et al. Angiographic coronary artery disease is associated with progressively higher levels of fasting plasma glucose. Diabetes Res Clin Pract. 2007;75:207–213.
  2. Bittencourt C, Piveta VM, Oliveira CS, et al. Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography. Diabetol Metab Syndr. 2014;6:46–54.
  3. Gui MH, Qin GY, Ning G, et al. The comparison of coronary angiographic profiles between diabetic and nondiabetic patients with coronary artery disease in a Chinese population. Diabetes Res Clin Pract. 2009;85:213–219.
  4. Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19–28.
  5. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008;45:1–16.
  6. Trevisan M, Browne R, Ram M, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001;154:348–356.
  7. Ciuchi E, Odetti P, Prando R. Relationship between glutathione and sorbitol concentrations in erythrocytes from diabetic patients. Metabolism. 1996;45:611–613.
  8. Cavalca V, Veglia F, Squellerio I, et al. Glutathione, vitamin E and oxidative stress in coronary artery disease: Relevance of age and gender. Eur J Clin Invest. 2009;39:267–272.
  9. Damy T, Kirsch M, Khouzami L, et al. Glutathione deficiency in cardiac patients is related to the functional status and structural cardiac abnormalities. PLoS One. 2009;4:e4871–4878.
  10. Pietruszyński R, Markuszewski L, Masiarek K, Makowski M, Retelewska W, Watala C. Role of preprocedural glutathione concentrations in the prediction of major adverse cardiac events in patients with acute coronary syndrome treated with percutaneous coronary intervention. Pol Arch Med Wewn. 2013;123:228–237.
  11. Powell LA, Warpeha KM, Xu W, Walker B, Trimble ER. High glucose decreases intracellular glutathione concentrations and upregulates inducible nitric oxide synthase gene expression in intestinal epithelial cells. J Mol Endocrinol. 2004;33:797–803.
  12. Bald E, Głowacki R. 2-Chloro-1-methylquinolinium tetrafluoroborate as an effective and thiol specific UV-tagging reagent for liquid chromatography. J Liq Chromatogr Related Technol. 2001;24:1323–1339.
  13. Karolczak K, Kamysz W, Karafova A, Drzewoski J, Watala C. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: A randomized multicenter study. Pharmacol Res. 2013;74:7–22.
  14. Karolczak K, Pietruszyński R, Drzewoski J, Kasznicki J, Watala C. Aspirin dose increase from 75 to 150 mg suppresses red blood cell contribution to suboptimal platelet response to aspirin in patients with CAD. Cardiovasc Drugs Ther. 2013;27:549–558.
  15. Ando Y, Steiner M. Sulfhydryl and disulfide groups of platelet membranes. I. Determination of sulfhydryl groups. Biochim Biophys Acta. 1973;311:26–37.
  16. Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 1990;186:464–478.
  17. Rice-Evans CA, Diplock AT, Seymons MCR. Techniques in free radical research. Amsterdam, London, New York (NY), Tokyo: Elsevier; 1991.
  18. Cerielo A, Motz E, Cavarape A, et al. Hyperglycemia counterbalances the antihypertensive effect of glutathione in diabetic patients: Evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. J Diabetes Complications. 1997;11:250–255.
  19. Ceriello A, Bortolotti N, Crescentini A, et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest. 1998;28:329–333.
  20. Tessier D, Khalil A, Fülöp T. Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J Gerontol A Biol Sci Med Sci. 1999;54:M541–545.
  21. Konukoğlu D, Hatemi H, Ozer EM, Gönen S, Akçay T. The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest. 1997;20:471–475.
  22. Barbagallo M, Dominguez LJ, Tagliamonte MR, Resnick LM, Paolisso G. Effects of vitamin E and glutathione on glucose metabolism: Role of magnesium. Hypertension. 1999;34:1002–1006.
  23. Arranz L, Fernández C, Rodríguez A, Ribera JM, De la Fuente M. The glutathione precursor N-acetylcysteine improves immune function in postmenopausal women. Free Radic Biol Med. 2008;45:1252–1262.
  24. Lavoie S, Murray MM, Deppen P, et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology. 2008;33:2187–2199.
  25. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37:117–123.
© Wroclaw Medical University